Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open‐label CADMUS Jr study

Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial

(2017) Kim Papp et al.   LANCET

Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study

(2015) Ian Landells et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases

(2015) Michele W L Teng et al.   NATURE MEDICINE

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

(2013) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence

(2012) Rosa Parisi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use

(2010) M.S. LEWIS-JONES et al.   BRITISH JOURNAL OF DERMATOLOGY

No evidence found that childhood onset of psoriasis influences disease severity, future body mass index or type of treatments used

(2010) MEA De Jager et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Epidemiology and comorbidity of psoriasis in children

(2009) M. Augustin et al.   BRITISH JOURNAL OF DERMATOLOGY

Epidemiology and prescribed treatments in childhood psoriasis: A survey among medical professionals

(2009) Michelle E. A. De Jager et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET

Etanercept Treatment for Children and Adolescents with Plaque Psoriasis

(2008) Amy S. Paller et al.   NEW ENGLAND JOURNAL OF MEDICINE